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Abstract
Background
The leishmanicidal action of tricyclic antidepressants has been studied and evidences have
pointed that their action is linked to inhibition of trypanothione reductase, a key enzyme in
the redox metabolism of pathogenic trypanosomes. Cyclobenzaprine (CBP) is a tricyclic
structurally related to the antidepressant amitriptyline, differing only by the presence of a
double bond in the central ring. This paper describes the effect of CBP in experimental vis-
ceral leishmaniasis, its inhibitory effect in trypanothione reductase and the potential immu-
nomodulatory activity.
Methodology/Principal Findings
In vitro antileishmanial activity was determined in promastigotes and in L. infantum-infected
macrophages. For in vivo studies, L. infantum-infected BALB/c mice were treated with CBP
by oral gavage for five days and the parasite load was estimated. Trypanothione reductase
activity was assessed in the soluble fraction of promastigotes of L. infantum. For evaluation
of cytokines, L. infantum-infected macrophages were co-cultured with BALB/c splenocytes
and treated with CBP for 48 h. The supernatant was analyzed for IL-6, IL-10, MCP-1, IFN-γ
and TNF-α. CBP demonstrated an IC50 of 14.5±1.1μM and an IC90 of 74.5±1.2 μM in pro-
mastigotes and an IC50 of 12.6±1.05 μM and an IC90 of 28.7±1.3 μM in intracellular amasti-
gotes. CBP also reduced the parasite load in L. infantum-infected mice by 40.4±10.3% and
66.7±10.5% in spleen at 24.64 and 49.28 mg/kg, respectively and by 85.6±5.0 and 89.3
±4.8% in liver at 24.64 and 49.28mg/kg, after a short-term treatment. CBP inhibited the try-
panothione reductase activity with a Ki of 86 ± 7.7 μM and increased the ROS production in
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promastigotes. CBP inhibited in 53% the production of IL-6 in infected macrophages co-
culture.
Conclusion/Significance
To the best of our knowledge, this study is the first report of the in vivo antileishmanial activ-
ity of the FDA-approved drug CBP. Modulation of immune response and induction of oxida-
tive stress in parasite seem to contribute to this efficacy.
Author Summary
Leishmaniasis is the denomination of a worldwide widespread group of tropical neglected
diseases caused by protozoa belonging to Leishmania genus. Several factors have com-
peted to worsen its spreading, such as climate changes and the recent conflict in Syria.
The visceral form is the most severe among them and it is fatal if untreated. There is no
vaccine for humans and the therapeutic arsenal is quite limited. Drug repurposing is a
strategy that aims to look for new uses for well stablished drugs. This approach has been
pointed as an attractive option to fasten the development of new treatment for leishmania-
sis. Here, the authors evaluated the activity of cyclobenzaprine (CBP), a classical muscle
relaxant, in a murine model of visceral leishmaniasis and investigated mechanisms
involved in its leishmanicidal action. CBP was effective in reducing the parasite burden
both in cell culture and in the liver and spleen of Leishmania-infected mice. Furthermore,
the experimental data suggested that CBP interferes in the redox balance of the parasite
and modulates the immune response of the host. Altogether, these results encourage fur-
ther studies to evaluate the therapeutic usage of cyclobenzaprine for leishmaniasis.
Introduction
The research and development of new drugs is a slow and costly process. In addition to the dif-
ferent clinical forms caused by over 20 species of Leishmania, the drug resistance increases the
complexity of the challenge [1]. Drug repurposing is an interesting strategy to speed up and
reduce costs in Drug Discovery and Development [2]. Since the 1980s, the antileishmanial
action of tricyclic drugs has been studied [3] and there are evidences that their action is linked
to inhibition of trypanothione reductase [4], a key enzyme in the redox metabolism of patho-
genic trypanosomes [5]. Cyclobenzaprine is a skeletal muscle relaxant, structurally related to
the tricyclic compound amitriptyline, differing only by the presence of a double bond in the
central ring. Within this context, we demonstrated the effect of cyclobenzaprine in experimen-
tal visceral leishmaniasis, and studied the potential inhibitory effect in trypanothione reductase
and also the immunomodulatory activity.
Materials and Methods
Ethics statement
This study was performed in accordance with the guidelines of the Guide for the Care and
Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation
(COBEA) and had the approval of the Animal Ethics Committee of Oswaldo Cruz Foundation
(license number L-026/2015).
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Parasites
The Leishmania infantum (MHOM/MA/67/ITMAP-263) used in this study is a well-estab-
lished strain and was kindly provided by Instituto de Biologia Molecular e Celular, Porto Uni-
versity, Portugal.
Chemicals
Cyclobenzaprine (CBP), DTNB (Ellman’s reagent), propidium iodide (PI), resazurin, lipopoly-
saccharide (LPS), concanavalin A (ConA), miltefosine and rhodamine 123 were purchased
from Sigma–Aldrich (St Louis, USA), 20,70-dichlorodihydrofluorescein diacetate (H2DCFDA)
from Molecular Probes (Eugene, USA), and Glucantime from Sanofi-Aventis (São Paulo,
Brazil).
In vitro antileishmanial assays
Promastigotes of L. infantum (strain MHOM/MA/67/ITMAP-263) at 1.0x106 cells/mL were
cultivated with cyclobenzaprine in triplicate (0–50 μM) at 26˚C in Schneider’s medium
(Sigma-Aldrich) supplemented with 20% heat-inactivated fetal calf serum (HIFCS), for 72 h.
Inhibition of parasite growth was assessed employing resazurin [6].
For the intracellular amastigote assay, resident peritoneal macrophages were collected from
BALB/c mice, plated in RPMI (Sigma-Aldrich) at 2x106 cells/mL in duplicate, infected with
promastigotes of L. infantum (5:1) and incubated at 37˚C in 5% CO2 for 4 h. After washing,
macrophages were incubated with cyclobenzaprine for further 72 h. The slides were stained
and the amastigotes were counted using light microscopy.
Experimental visceral leishmaniasis
Dose Translation: The initial dose was calculated based on the human dose, as follows [7]: Ani-
mal dose (mg/kg) = (human Km / animal Km) x human dose (mg/kg), where mouse Km = 3,
human Km = 37.
Protocol: BALB/c mice (five per group) were infected intraperitoneally with 1.0x108 station-
ary-phase L. infantum promastigotes [8–10]. After 25 days, mice were treated with three CBP
doses (12.32, 24.64 and 49.28 mg/kg) by oral gavage for five days [11]. Control groups were
treated with miltefosine 20.55 mg/kg and vehicle (water). After the treatment, the animals
were euthanized and spleen and liver were aseptically removed and the parasite load was esti-
mated by limiting dilution assay (LDA) [12]. The serum levels of aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) were measured using laboratory colorimetric diag-
nostic kits (Doles, Goiaˆnia, Brazil).
Trypanothione reductase activity
The assay was adapted from Hamilton et al. [13]. Briefly, promastigotes of L. infantum were
centrifuged and resuspended in buffer containing 40 mM HEPES, 1 mM EDTA and protease
inhibitor cocktail (Sigma-Aldrich). The parasites were lysed and centrifuged at 17.500g/15
min. The supernatant was considered to contain the trypanothione reductase (TryR). The
assay was performed in triplicate with: 40 mM HEPES (pH 7.5), 1 mM EDTA, 100 μM of
DTNB (Ellman’s reagent), 1 μM substrate (trypanothione trifluoroacetate, Sigma-Aldrich), 0.1
mM NADPH and different concentrations of cyclobenzaprine (0–100μM). Reading was initi-
ated after adding 4 mg/mL soluble protein (enzyme) at 410nm using a Spectra Max M2
spectrofluorometer (Molecular Devices, Silicon Valley, CA, USA) at 10 min intervals for 1 h.
Clomipramine was used as positive control (PC). This drug has well-known action on the
Cyclobenzaprine Activity in Visceral Leishmaniasis
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inhibition of trypanothione reductase enzyme [14]. Apparent Ki was assumed to be the value
of the 50% inhibitory concentration obtained from the dose-response curve inhibition of TryR
by CBP in 60 minutes. Ki value was determined by nonlinear least-squares fitting of these data
to the 4-parameter logistic plot equation, as described by Holloway GA, Charman WN, Fair-
lamb AH, et al, (2009): y = A+{(B–A)/[1+(C/x)D]} [15].
Measurement of ROS
Intracellular ROS levels were measured as described by Ribeiro et al [16]. Briefly, 1×107 pro-
mastigotes/mL of L. infantum were incubated with CBP (0 to 50 μM) in the presence of 20 μM
H2DCFDA in Schneider’s medium with 20% HIFCS. The fluorescence was quantified at 1 h
intervals for 6 h.
Evaluation of cytokines and nitric oxide production
Briefly, macrophages obtained from peritoneal cavity were plated at 1x105 cells/mL in a 24
well plate with complete RPMI 1640 medium supplemented with 10% HIFCS and infected
overnight with amastigotes of L. infantum (ratio 10:1). After 18 hours of infection, macro-
phages were co-cultured with splenocytes obtained from BALB/c mouse at a ratio 1:6. Cells
were treated with a non-toxic concentration of CBP (100 μM) for 48 h. Afterwards, the cell
supernatant was analyzed for IL-6, IL-10, monocyte chemotactic protein-1 chemokine (MCP-
1), IFN-γ and TNF-α levels using flow cytometry and the Cytometric Beads Array (CBA) kit
(BD Bioscience, San Diego, CA, USA). Controls consisted of sham-treated macrophages
infected with L. infantum, LPS (1 μg/mL) and concanavalin A (1 μg/mL), and the negative con-
trol (macrophages without the drug). The nitric oxide content was colorimetrically determined
by the Griess reaction in the culture supernatants of peritoneal macrophages [17]. Cells were
treated for 24 h with cyclobenzaprine at 12 μM, corresponding to the IC50 value against intra-
cellular amastigotes. Bacterial lipopolysaccharide (LPS) was used as positive control (1 μg/mL).
The obtained results were extrapolated from a standard curve prepared with NaNO2 at differ-
ent concentrations (0 to 400 μM).
Statistical analysis. Results are represented as the mean and standard deviation of repli-
cates samples from at least two independent assays. IC50 values were calculated using sigmoi-
dal dose-response curves using GraphPad Prism 5.0 software. Test T was used for significance
testing (p<0.05).
Results
In vitro activity
CBP demonstrated a concentration-dependent activity in L. infantum promastigotes growth,
with an IC50 value of 14.5±1.1μM and an IC90 value of 74.5±1.2 μM (Fig 1A). The drug was
also effective against clinically relevant forms, the intracellular amastigotes, with an IC50 of
12.6±1.05 μM and an IC90 of 28.7±1.3 μM (Fig 1B). The treatment with 50 μM reduced this
index by 99% when compared to control (insert Fig 1B).
Experimental visceral leishmaniasis
Cyclobenzaprine was effective in reducing the parasite load by 40.4±10.3% and 66.7±10.5% in
spleen at 24.64 and 49.28 mg/kg, respectively (Fig 2A) and by 85.6±5.0 and 89.3±4.8% in liver
at 24.64 and 49.28mg/kg (Fig 2B), after a short-term treatment. We did not observe changes in
hepatic transaminases levels in groups treated with CBP. However, there was a significant
increase of ALT level in the group treated with 20.55 mg/kg of miltefosine.
Cyclobenzaprine Activity in Visceral Leishmaniasis
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Fig 1. In vitro activity of CBP. (A) Promastigotes of L. infantum were incubated with CBP for 72 h. The growth inhibition was measured
using resazurin. (n = 3) (B) Peritoneal macrophages were infected with L. infantum and treated with CBP for 72 h. The slides were stained
and the results were expressed as an infection index# [II = % infected cells × (number of amastigotes/total number of macrophages)]. The
inset shows representative photos from the slides. (n = 3).
doi:10.1371/journal.pntd.0005281.g001
Fig 2. In vivo activity of CBP. L. infantum-infected BALB/c mice were treated after 25 days of infection for 5 consecutive days, with CBP
12.32, 24.64 and 49.28mg/kg, by oral route. Control groups were treated with miltefosine 20.55mg/kg (reference drug—M20.55) and vehicle
(water). The parasite load was estimated using a parasite-limiting dilution assay (LDA) in spleen (A) and liver (B). The serum levels of aspartate
aminotransferase (AST) (C) and alanine aminotransferase (ALT) (D) after five days of treatment were measured using laboratory colorimetric
diagnostic kits (n = 5) *p<0.05; **p<0.01.
doi:10.1371/journal.pntd.0005281.g002
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Biochemical alterations of cyclobenzaprine on L. infantum
CBP inhibited the TryR activity in a concentration-dependent manner (Fig 3A), with a Ki of
86 ± 7.7 μM. CPB also increased the ROS production in promastigotes in a time and concen-
tration-dependent manner in the first 6 hours, consistent with TryR inhibition (Fig 3B).
Immunomodulatory activity
Flow cytometry data demonstrated that CBP inhibited the production of IL-6 in infected mac-
rophages, decreasing the production of this cytokine by 53% when compared to untreated
Fig 3. Effect of CBP on TryR and ROS production. (a) TryR assay. Soluble extract of promastigotes of L. infantum using oxidized trypanothione as
substrate and clomipramine (50 μM) as positive control (PC) of inhibition. Reading was initiated after adding 100 μM of DTNB at 410nm (n = 3). (b)
ROS production. Promastigotes of L. infantum were incubated with CBP and ROS generation was measured with H2DCFDA reagent. Antimycin A
10 μM was used as positive control (PC). (n = 3) *p<0.05, ** p<0.01 and ***p<0.001.
doi:10.1371/journal.pntd.0005281.g003
Cyclobenzaprine Activity in Visceral Leishmaniasis
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macrophages (Fig 4a and 4b). MCP-1 levels of macrophages co-cultured with splenocytes were
not altered by CBP treatment (Fig 4c and 4d). The control of cytokines production was con-
firmed in the LPS and ConA-treated groups. The treatment of macrophages with CBP resulted
in unaltered levels of TNF-α, IFN-γ and IL-10 (Fig 4e–4j). Griess assay demonstrated an upre-
gulation of nitric oxide levels of 3.2 times in macrophages incubated with CBP (Fig 5).
Discussion
Tricyclic antidepressants have shown potential against different Leishmania species with effec-
tiveness based on the three ring structure and potency relaying on specific molecular substitu-
tions. Amitriptyline, which lacks the nitrogen in the central ring, is 10-fold more active against
promastigotes of L. donovani than its nitrogen-substituted derivative, imipramine [18]. In this
work we demonstrated for the first time in literature the in vitro and in vivo antileishmanial
potential of cyclobenzaprine, a tricyclic derivative structurally related to amitriptyline. Our
data demonstrated that CPB was effective against the intracellular amastigotes of L. infantum,
with a IC50 value close to that reported for amitriptyline for L. donovani and L. amazonensis
intracellular amastigotes [19].
Trypanothione reductase is an essential component of the antioxidant defenses of trypano-
somatids [5]. Interestingly, some tricyclic antidepressants have been reported to inhibit the
TryR, as clomipramine, which showed a potent effect with a Ki of 6.53 μM on recombinant TR
from Trypanosoma cruzi [14]. Here, we demonstrated that CBP also inhibited L. infantum
TryR activity at similar Ki value to those reported for amitriptyline [14], but with a reduced
affinity when compared to clomipramine. Furthermore, it was also observed that promasti-
gotes treated with CBP increased the intracellular concentration of ROS, in the same concen-
tration range for TryR inhibition. Nevertheless, the concentration of CBP required to inhibit
TryR and to induce ROS accumulation in the first hours of incubation was higher to that
required to eliminate the parasites after 72 h. These data suggest a cumulative effect of inhibi-
tion of TryR at lower concentrations of CBP in 72 h or concomitant off-target effects of CBP
contributing to the parasite death.
Immunomodulatory activity of drugs has also been implicated in the parasite control. In
addition to the effective antileishmanial activity observed for CBP, its immunomodulatory
potential was evaluated. Considered as a positive effect for Leishmania control, our data
demonstrated that CPB induced a decrease of IL-6 levels in Leishmania-infected macro-
phages. Cytokines such as IL-6 and IL-10 play a critical role in regulating macrophage activa-
tion. Several clinical and experimental studies show that both IL-6 and IL-10 are involved in
pathogenesis of VL; elevated levels of IL-6 has been associated to a preceding death event in
VL patients [20]. It has also been reported that patients with active VL have higher serum lev-
els of IL-10 and IL-6, evidencing their association with disease persistence [21]. Other studies
with phenylpropanoid derivatives, demonstrated a correlation between the downregulation
of IL-6 and IL-10 with the control of the infection in the Leishmania-infected macrophages
[22]. Jek and co-workers [23] demonstrated that blocking NO production in rat macro-
phages results in an increased IL-1 and IL-6 secretion. Our assays demonstrated an upregula-
tion of NO levels in macrophages incubated with CBP. The potential anti-inflammatory
effect of nitric oxide has been described in human alveolar macrophages, followed by a
downregulation of proinflammatory cytokines, including IL-6 [24, 25]. Based in these data,
we could hypothesize that the antileshmanial effect of CBP involves an immunomodulatory
effect in macrophages, increasing NO levels which consequently reduces an exacerbatory
cytokine (IL-6) in leishmaniasis.
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Fig 4. In vitro immunomodulation of CBP. Leishmania-infected (B, D, F, H and J) and uninfected
macrophages (A, C, E, G and I), co-cultured or not with splenocytes and treated with 100 μM of CBP; MØ
(macrophages), Spl (splenocytes); LPS (lipopolysaccharide); Cona (concanavalin A). Cytokine levels were
measured by CBA (cytometric beads array—BD Biosciences) in supernatant of cells after 48 h. Spl were not
infected with Leishmania. (A and B) IL-6, (C and D) MCP-1, (E and F) TNF-α, (G and H) INF-γ and (I and J) IL-
10. Cytokine levels were expressed as a significant experiment of two independent assays (n = 2). *p<0.05.
doi:10.1371/journal.pntd.0005281.g004
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Conclusion
To the best of our knowledge, this study is the first report of the in vitro and in vivo antileish-
manial activity of the FDA-approved drug CBP. Modulation of macrophage immune response
and induction of oxidative stress in parasite seem to contribute to this efficacy, but additional
effects may be further investigated. Altogether, these findings point out CBP as a candidate for
further studies against visceral leishmaniasis.
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